Barriers to progress--the impact of tolerability problems.

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Trials

Background:

• Antipsychotic treatment adherence is crucial and influenced by side effects like extrapyramidal symptoms (EPS), weight gain, and sexual dysfunction.
• Atypical antipsychotics offer improved tolerability over conventional neuroleptics, particularly regarding EPS.
• Differences in receptor binding profiles among novel antipsychotics lead to varied side-effect profiles.

Purpose of the Study:

• To evaluate the side-effect profile of ziprasidone, a novel atypical antipsychotic.
• To assess ziprasidone's liability for adverse events associated with poor patient compliance.
• To compare the tolerability of ziprasidone with older neuroleptics.

Main Methods:

• Analysis of short- and long-term clinical trial data for ziprasidone.
• Evaluation of ziprasidone's receptor binding characteristics, including affinities for 5-HT2, D2, muscarinic (M1), histaminergic (H1), and alpha1-adrenergic receptors.
• Assessment of side-effect profiles related to patient compliance.

Main Results:

• Ziprasidone demonstrated a low liability for extrapyramidal symptoms (EPS), weight gain, and sexual dysfunction.
• The drug exhibits minimal activity at receptors linked to sedation, postural hypotension, weight gain, and cognitive impairment.
• Ziprasidone's high 5-HT2 to D2 receptor binding ratio is associated with a low potential for EPS.

Conclusions:

• Ziprasidone presents a favorable tolerability profile, suggesting improved patient compliance.
• Novel antipsychotics, including ziprasidone, represent a significant advancement over older neuroleptics in terms of side-effect management.
• Improved benefit/risk ratios of newer antipsychotics are likely to enhance patient outcomes.